NLG919
NLG919 Basic information
- Product Name:
- NLG919
- Synonyms:
-
- 5-(2-Cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,1-a]isoindole
- NLG919(GDC-0919,Navoximod)
- CS-820
- GDC 0919
- GDC0919
- GDC-0919
- NLG-919; NLG 919; IDO INHIBITOR;GDC-0919;GDC 0919;GDC0919
- NLG919
- CAS:
- 1402836-58-1
- MF:
- C18H22N2O
- MW:
- 282.38
- EINECS:
- 1592732-453-0
- Product Categories:
-
- Inhibitor
- Inhibitors
- Mol File:
- 1402836-58-1.mol
NLG919 Chemical Properties
- Melting point:
- 143 - 146°C
- Boiling point:
- 524.6±33.0 °C(Predicted)
- Density
- 1.27±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to 15 mg/ml)
- form
- solid
- pka
- 14.85±0.20(Predicted)
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
NLG919 Usage And Synthesis
Description
(±)-NLG-919 is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor (Ki = 7 nM; EC50 = 75 nM). (±)-NLG-919 inhibits IDO-induced T cell suppression and restores T cell response during allogenic mixed lymphocyte reactions in vitro (ED50s = 80 and 120 nM, respectively). In vivo, (±)-NLG-919 induces a 95% reduction in tumor volume when administered in conjunction with a pmel-1 T cell vaccine. Formulations containing (±)-NLG-919 are under investigation in clinical trials for treatment of glioblastoma, melanoma, pancreatic, and breast cancers.
Uses
NLG919 is a potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitor and is suitable for the treatment of immunosuppression associated with cancer.
target
IDO pathway
References
1) Mautino?et al.?(2013),?NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy;?Cancer Res.?73?issue 8 supplement?491 2) Li?et al.?(2014),?The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma;?J. Immunother. Cancer?2?21 3) Meng?et al.?(2017),?Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model;?Int. J. Immunopathol. Pharmacol.?30?215
NLG919Supplier
- Tel
- 13621943973
- sales@shjiyipharmatech.com
- Tel
- 13621943973; 13621943973
- sales@jamxmpharmatech.com
- Tel
- 13549236410
- sales@invivochem.cn
- Tel
- sales@boylechem.com
- Tel
- 021-021-58432009 400-005-6266
- sales8178@energy-chemical.com